Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.46 |
| ▸ | CA12 | O43570 | 9/20 | 0.46 |
| ▸ | CA9 | Q16790 | 9/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.44 |
| ▸ | CA1 | P00915 | 7/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000674 | 0.86 | PTGS2 (0.48) | PTGS2 | |
| SCHEMBL7000106 | 0.83 | CA2 (0.53) | CA2CA12CA9PTGS2CA1 | |
| SCHEMBL6995245 | 0.82 | PTGS2 (0.44) | CA2CA12CA9PTGS2CA1 | |
| SCHEMBL12169141 | 0.80 | ELANE (0.39) | PTGS2MEN1KMT2A | |
| SCHEMBL6999688 | 0.79 | PTGS2 (0.60) | CA2CA12CA9PTGS2CA1 | |
| SCHEMBL7002002 | 0.78 | PTGS2 (0.56) | CA2CA12CA9PTGS2CA1 | |
| SCHEMBL1420038 | 0.78 | PGR (0.41) | PTGS2KDM4E | |
| SCHEMBL7003386 | 0.77 | CA2 (0.49) | CA2CA12CA9PTGS2CA1 | |
| SCHEMBL6998878 | 0.77 | PTGS2 (0.57) | CA2CA12CA9PTGS2CA1 | |
| SCHEMBL6992672 | 0.77 | PTGS2 (0.51) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111419818-A | Pharmaceutical composition comprising furanone and capsule formulation comprising the same | 晶体基因技术株式会社 | 2020-07-17 | — | — | CN | disclosed |
| US-10413520-B2 | Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability | CRYSTALGENOMICS, INC. (KR) | 2019-09-17 | — | — | US | disclosed |
| EP-3099294-B1 | PHARMACEUTICAL COMPOSITION INCLUDING 5-{4-(AMINOSULFONYL)PHENYL}-2,2-DIMETHYL-4-(3-FLUOROPHENYL)-3(2H)-FURANONE AND CAPSULE FORMULATION INCLUDING THE PHARMACEUTICAL COMPOSITION | CRYSTALGENOMICS INC (KR) | 2018-08-01 | — | — | EP | disclosed |
| US-20180008571-A1 | Oral Pharmacological Composition Including 5--2,2-Dimethyl-4-(3-Fluorophenyl)-3(2H)-Furanone Having Crystalline Structure With Excellent Stability | CRYSTALGENOMICS, INC. (KR) | 2018-01-11 | — | — | US | disclosed |
| US-20170000759-A1 | Pharmaceutical Composition Including 5--2,2-Dimethyl-4-(3-Fluorophenyl)-3(2H)-Furanone And Capsule Formulation Including The Pharmaceutical Composition | CRYSTALGENOMICS, INC. (KR) | 2017-01-05 | — | — | US | disclosed |
| EP-3099294-A1 | PHARMACEUTICAL COMPOSITION INCLUDING 5-{4-(AMINOSULFONYL)PHENYL}-2,2-DIMETHYL-4-(3-FLUOROPHENYL)-3(2H)-FURANONE AND CAPSULE FORMULATION INCLUDING THE PHARMACEUTICAL COMPOSITION | Crystalgenomics Inc. (KR) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015115853-A1 | PHARMACEUTICAL COMPOSITION INCLUDING 5-{4-(AMINOSULFONYL)PHENYL}-2,2-DIMETHYL-4-(3-FLUOROPHENYL)-3(2H)-FURANONE AND CAPSULE FORMULATION INCLUDING THE PHARMACEUTICAL COMPOSITION | CRYSTALGENOMICS, INC. (KR) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180008571-A1 | Oral Pharmacological Composition Including 5--2,2-Dimethyl-4-(3-Fluorophenyl)-3(2H)-Furanone Having Crystalline Structure With Excellent Stability | IL5, CYP3A5, SULT1E1 | CA2 1072/4885CA12 3338/4885CA9 2076/4885 |
| US-10413520-B2 | Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability | IL5, SULT1E1, CYP2C19 | CA2 1319/4885CA12 3430/4885CA9 1776/4885 |
| US-20170000759-A1 | Pharmaceutical Composition Including 5--2,2-Dimethyl-4-(3-Fluorophenyl)-3(2H)-Furanone And Capsule Formulation Including The Pharmaceutical Composition | IL5, F5, CYP3A5 | CA2 1529/4885CA12 2571/4885CA9 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.